The newest data have reported that the small-molecule inhibitor of the PERK-dependent signaling pathway LDN-0060609, selected from the Laboratory for Drug Discovery in Neurodegeneration (LDDN) compound library, may constitute a novel, ground-breaking treatment strategy against neurodegenerative diseases, especially AD. Here, EIF2AK3 is linked to Alzheimer disease.